Overview

Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
To investigate the bioequivalence between two formulations containing S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys) when administered as single oral dose in two consecutive study periods to healthy male and female volunteers under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A
Collaborator:
Cross Research S.A.
Treatments:
Carbocysteine
Pharmaceutical Solutions